Big pharma, Diagnostics, Partnering, Pharma

Johnson & Johnson, Janssen Biotech and Icahn School of Medicine at Mount Sinai enter IBD pharma deals

Posted on 28 June 2013

Tags: , , ,

Janssen Biotech and Johnson & Johnson announced pharma deals with Icahn School of Medicine at Mount Sinai to advance scientific understanding of inflammatory bowel disease and discover next generation therapeutic solutions.

Scientists from the Janssen Immunology Therapeutic Area and researchers from Mount Sinai will work on pharma deals to investigate disease triggers, identify new opportunities for therapeutic interventions and establish diagnostics to facilitate precision medicine and predictive biomarkers.

The first-of-its-kind industry and academic partnership brings together Janssen research and development capabilities with an early-stage life science investment through the Johnson & Johnson Innovation center in Boston and Mount Sinai's expertise in computational biology, and clinical and translational research in IBD as part of the pharma deals.

The pharma deals collaboration will focus on building a Molecular Interaction Network of Disease in IBD with the breadth and depth to yield high confidence therapeutic hypotheses to be tested in vitro and in vivo.

Using preclinical models, clinical study data and patient samples, a dedicated group of Janssen and Mount Sinai researchers, computational biologists and translational medicine scientists will develop clinical methodologies to test hypotheses and identify potential therapeutic candidates as part of the pharma deals.

This unique industry and academic research alliance brings together scientific and institutional resources from Mount Sinai, Janssen and Johnson & Johnson Innovation representing each organization's deep commitment and investment in transforming the treatment of IBD.

Related

Report: Inflammatory Bowel Disease Partnering

Report: Partnering Deals and Alliances with Johnson & Johnson / Janssen

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply